Novavax (NASDAQ: NVAX) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Novavax and ANI Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novavax 0 6 2 0 2.25
ANI Pharmaceuticals 0 1 2 0 2.67

Novavax presently has a consensus price target of $2.85, suggesting a potential upside of 168.51%. ANI Pharmaceuticals has a consensus price target of $65.33, suggesting a potential upside of 41.23%. Given Novavax’s higher possible upside, analysts clearly believe Novavax is more favorable than ANI Pharmaceuticals.

Insider and Institutional Ownership

45.2% of Novavax shares are held by institutional investors. Comparatively, 55.9% of ANI Pharmaceuticals shares are held by institutional investors. 4.0% of Novavax shares are held by company insiders. Comparatively, 31.8% of ANI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Novavax and ANI Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Novavax $21.04 million 14.82 -$186.64 million ($0.77) -1.38
ANI Pharmaceuticals $158.12 million 3.40 $59.01 million $0.46 100.57

ANI Pharmaceuticals has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Novavax and ANI Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Novavax -1,006.00% -787.38% -53.89%
ANI Pharmaceuticals 3.35% 22.70% 11.48%

Risk & Volatility

Novavax has a beta of 1.94, meaning that its share price is 94% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 3.08, meaning that its share price is 208% more volatile than the S&P 500.

Summary

ANI Pharmaceuticals beats Novavax on 10 of the 12 factors compared between the two stocks.

Novavax Company Profile

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company’s product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company’s lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

Receive News & Stock Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related stocks with our FREE daily email newsletter.